---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-020353"
form_type: "8-K"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2025-05-23T23:59:59+00:00"
generated_at: "2026-05-20T13:11:07.389493+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Gyre Therapeutics raises $20M in public offering for Phase 2 F351 trial

## Summary
- Issued 2,222,222 shares at $9.00/share; underwriters have 30-day option for 333,333 additional shares.
- Net proceeds estimated at $18.5M after discounts and expenses.
- Funds U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis, R&D, and working capital.
- Offering expected to close May 27, 2025; Jefferies LLC is sole book-running manager.

## SEC filing metadata
- accession: 0001140361-25-020353
- form_type: 8-K
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2025-05-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000114036125020353/0001140361-25-020353-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000114036125020353/ef20049643_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-020353
- JSON: https://secwatch.observer/filing/0001140361-25-020353.json
- Plain text: https://secwatch.observer/filing/0001140361-25-020353.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.